Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 16/20 | 0.59 |
| ▸ | CTPS2 | Q9NRF8 | 4/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | LGMN | Q99538 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491620 | 1.00 | CTPS1 (0.59) | CTPS1CTPS2PIK3CDDYRK1AGPR55 | |
| SCHEMBL30528934 | 0.92 | CTPS1 (0.61) | CTPS1CTPS2DYRK1AGPR55 | |
| SCHEMBL22762616 | 0.92 | CTPS1 (0.61) | CTPS1CTPS2DYRK1AGPR55 | |
| SCHEMBL22491696 | 0.88 | CTPS1 (0.77) | CTPS1CTPS2 | |
| SCHEMBL30528746 | 0.88 | CTPS1 (0.77) | CTPS1CTPS2 | |
| SCHEMBL22491649 | 0.86 | CTPS1 (0.78) | CTPS1CTPS2 | |
| SCHEMBL30528929 | 0.86 | CTPS1 (0.78) | CTPS1CTPS2 | |
| SCHEMBL22491631 | 0.81 | CTPS1 (0.65) | CTPS1CTPS2 | |
| SCHEMBL21044332 | 0.80 | CTPS1 (0.72) | CTPS1CTPS2 | |
| SCHEMBL30528739 | 0.80 | CTPS1 (0.72) | CTPS1CTPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | claimed |
| EP-4637770-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | Step Pharma S.A.S. (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4486347-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | Step Pharma S.A.S. (FR) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804752-A | Combination of CTPS1 and BCL2 inhibitors for the treatment of cancer | 斯泰普制药股份公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166080-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166077-A1 | COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |